Skip to main content
. 2022 Jul 28;145(9):3288–3307. doi: 10.1093/brain/awac222

Figure 1.

Figure 1

TAA depletion regress GBM progression. (A) Representative immunofluorescence images of reactive TAAs stained for GFAP (cyan) crowning a glioblastoma (GBM) tumour (GFP+-GL261, white), and nuclei (DAPI, yellow). The right image is an expansion of the area marked by the white box. (n = 3 biologically independent experiments, three mice per group). Scale bar = 1000 μm. (B–G) Wild-type (WT), or Gfap-TK GBM-bearing mice were treated daily with GCV (25 mg/kg) from Day 10 until the experimental end point as illustrated in B. (C) representative immunofluorescence images of reactive-astrocyte depletion at the tumour margins (GFP+-GL261, white), as detected by GFAP (cyan) and nuclei staining (DAPI, yellow). Scale bars = 500 μm. Data are representative of three independent experiments with n = 4 mice/group. (D and E) Tumour size in GCV-treated wild-type or Gfap-TK GBM-bearing littermates. (D) Representative images of GL261-derived bioluminescence from each group are shown on the left and quantification of tumour size on the right. Data are representative of five independent experiments with n = 6 mice/group. (E) Representative images from each group, 17 days after GL261 cell implantation, are shown on the left with quantification of tumour size on the right, tumour (GL261 cells in purple) and nuclei (DAPI; white). Scale bar = 1000 μm. Data are representative of three independent experiments with n = 5 mice/group. (F) Bodyweight assessment of mice from D. (G) Kaplan–Meier curves assessing overall survival. Data are representative of three independent experiments with n = 8 mice/group. Data in D–F are shown as mean ± SEM. P-values were determined by two-way ANOVA (D–F) or log rank (Mantel–Cox) test (G). *P < 0.05, **P < 0.01, ***P < 0.001, n.s. = not significant.